Treatment Challenges in Alopecia Areata: Insights From a Case of Baricitinib Therapy Failure

Alopecia areata (AA) is a difficult condition to treat, traditionally managed with corticosteroids and immunosuppressants. The FDA's approval of baricitinib, a Janus kinase inhibitor (JAKi), was a major advancement, showing promising results in clinical trials. However, this article discusses a rare case of a 30-year-old male with severe patch-type AA who, despite initially responding well to baricitinib, experienced a relapse while still on the treatment. This case highlights the challenges and potential limitations of baricitinib therapy in AA management.